Common chromosomal fragile site gene WWOX in metabolic disorders and tumors

International Journal of Biological Sciences

Volumn 10, Issue 2, 2014, Pages 142-148

  Li, Juan ^a   Liu, Jie ^a   Ren, Yu ^a   Yang, Jin ^a   Liu, Peijun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Endocrine and chemotherapy; Metabolic disorders; Tumorigenesis; WW domain containing oxidoreductase

Indexed keywords

OXIDOREDUCTASE; TUMOR SUPPRESSOR PROTEIN; WWOX PROTEIN, HUMAN;

CARCINOGENESIS; CHEMISTRY; CHROMOSOME FRAGILE SITE; ENDOCRINE AND CHEMOTHERAPY.; GENETICS; GENOMIC INSTABILITY; HUMAN; METABOLIC DISORDER; METABOLIC DISORDERS; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; REVIEW; TUMOR INVASION; WW DOMAIN-CONTAINING OXIDOREDUCTASE;

ENDOCRINE AND CHEMOTHERAPY.; METABOLIC DISORDERS; TUMORIGENESIS; WW DOMAIN-CONTAINING OXIDOREDUCTASE;

CHROMOSOME FRAGILE SITES; GENOMIC INSTABILITY; HUMANS; METABOLIC DISEASES; NEOPLASM INVASIVENESS; NEOPLASMS; OXIDOREDUCTASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEINS;

EID: 84892417754     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7727     Document Type: Review

References (55)

1. Dillon LW, Burrow AA, Wang YH. DNA instability at chromosomal fragile sites in cancer. Current genomics. 2010; 11: 326-37.
2. Lukusa T, Fryns JP. Human chromosome fragility. Biochimica et biophysica acta. 2008; 1779: 3-16.
3. Durkin SG, Glover TW. Chromosome fragile sites. Annual review of genetics. 2007; 41: 169-92.
4. Popescu NC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer letters. 2003; 192: 1-17.
5. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Seminars in cancer biology. 2007; 17: 31-41.
6. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends in molecular medicine. 2007; 13: 12-22.
7. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer research. 2003; 63: 8629-33.
8. Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. Journal of cellular physiology. 2010; 224: 327-33.
9. Chang NS, Schultz L, Hsu LJ, Lewis J, Su M, Sze CI. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene. 2005; 24: 714-23.
10. Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer research. 2005; 65: 10514-23.
11. Aqeilan RI, Hagan JP, de Bruin A, Rawahneh M, Salah Z, Gaudio E, et al. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology. 2009; 150: 1530-5.
12. Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 3949-54.
13. Ferguson BW, Gao X, Kil H, Lee J, Benavides F, Abba MC, et al. Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. PloS one. 2012; 7: e36618.
14. Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, Palumbo T, et al. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. The Journal of biological chemistry. 2008; 283: 21629-39.
15. Ludes-Meyers JH, Kil H, Parker-Thornburg J, Kusewitt DF, Bedford MT, Aldaz CM. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PloS one. 2009; 4: e7775.
16. Suzuki H, Katayama K, Takenaka M, Amakasu K, Saito K, Suzuki K. A spontaneous mutation of the Wwox gene and audiogenic seizures in rats with lethal dwarfism and epilepsy. Genes, brain, and behavior. 2009; 8: 650-60.
17. Del Mare S, Kurek KC, Stein GS, Lian JB, Aqeilan RI. Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. American journal of cancer research. 2011; 1: 585-94.
18. Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer research. 2010; 70: 5577-86.
19. Lin JT, Tzai TS, Liao CY, Wang JS, Wu TT, Wang HY, et al. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC. Annals of surgical oncology. 2013; 20: 193-9.
20. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer letters. 2006; 232: 27-36.
21. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC cancer. 2005; 5: 64.
22. Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, et al. A role for the WWOX gene in prostate cancer. Cancer research. 2006; 66: 6477-81.
23. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006; 32: 153-7.
24. Paige AJ, Zucknick M, Janczar S, Paul J, Mein CA, Taylor KJ, et al. WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. Eur J Cancer. 2010; 46: 818-25.
25. Guler G, Uner A, Guler N, Han S-Y, Iliopoulos D, Hauck WW, et al. The fragile genesFHIT andWWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004; 100: 1605-14.
26. Płuciennik E, Kusińska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX-the FRA16D cancer gene: Expression correlation with breast cancer progression and prognosis. European Journal of Surgical Oncology. 2006; 32: 153-7.
27. Nunez MaI. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast cancer research and treatment. 2005; 89: 99-105.
28. Nunez MI, Ludes-Meyers J, Aldaz CM. WWOX protein expression in normal human tissues. Journal of molecular histology. 2006; 37: 115-25.
29. Kuroki T. The Tumor Suppressor Gene WWOX at FRA16D Is Involved in Pancreatic Carcinogenesis. Clinical Cancer Research. 2004; 10: 2459-65.
30. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer. 2005; 5: 64.
31. Lin JT, Tzai TS, Liao CY, Wang JS, Wu TT, Wang HY, et al. WWOX Protein Expression Varies Among RCC Histotypes and Downregulation of WWOX Protein Correlates with Less-Favorable Prognosis in Clear RCC. Ann Surg Oncol. 2012; 20: 193-9.
32. Kuroki T TF, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 2002; 15: 2258-60.
33. Yendamuri S KT, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, Kaiser LR, Croce CM. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer research. 2003; 15: 878-81.
34. Ishii H, Mimori K, Vecchione A, Sutheesophon K, Fujiwara T, Mori M, et al. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. Biochemical and biophysical research communications. 2004; 316: 1088-93.
35. Taketo MM. Shutting down Wnt signal-activated cancer. NATURE GENETICS. 2004; 36: 320-2.
36. Bouteille N, Driouch K, El Hage P, Sin S, Formstecher E, Camonis J, et al. Inhibition of the Wnt/β-catenin pathway by the WWOX tumor suppressor protein. Oncogene. 2009; 28: 2569-80.
37. Kosla K, Pluciennik E, Kurzyk A, Jesionek-Kupnicka D, Kordek R, Potemski P, et al. Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. Journal of neuro-oncology. 2011; 101: 207-13.
38. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, et al. Association of Wwox with ErbB4 in breast cancer. Cancer research. 2007; 67: 9330-6.
39. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer research. 2004; 64: 8256-61.
40. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 4401-6.
41. Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM, et al. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer research. 2006; 66: 11585-9.
42. Salah Z, Bar-mag T, Kohn Y, Pichiorri F, Palumbo T, Melino G, et al. Tumor suppressor WWOX binds to DeltaNp63alpha and sensitizes cancer cells to chemotherapy. Cell death & disease. 2013; 4: e480.
43. Lin HP, Chang JY, Lin SR, Lee MH, Huang SS, Hsu LJ, et al. Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. Genes & cancer. 2011; 2: 550-62.
44. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004; 100: 1605-14.
45. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, et al. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast cancer research and treatment. 2011; 129: 421-32.
46. Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J, et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer research. 2009; 69: 4835-42.
47. Zhang JQ, Li L, Song HL, Paige A, Gabra H. Effect of WWOX gene on the attachment and adhesion of ovarian cancer cells. Zhonghua fu chan ke za zhi. 2009; 44: 529-32.
48. Göthlin Eremo A, Wegman P, Stål O, Nordenskjöld B, Fornander T, Wingren S. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncology reports. 2013; 29: 1467-74.
49. Orlandoa L., Schiavonea P., Fedelea P., et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treatment Reviews. 2010; 36S3: 67-71.
50. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast cancer research and treatment. 2005; 89: 99-105.
51. Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, Slingerland J, et al. WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol. 2006; 20: 2343-54.
52. McDonald CB, Buffa L, Bar-Mag T, Salah Z, Bhat V, Mikles DC, et al. Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors. Journal of molecular biology. 2012; 422: 58-74.
53. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2gamma expression levels predict tamoxifen response. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 6115-21.
54. Zangen R, Ratovitski E, Sidransky D. ΔNp63α Leves Correlate with Clinical Tumor Response to Cisplatin. Cell cycle. 2005; 4: 1313-15.
55. Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, et al. DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer research. 2011; 71: 1167-76.